Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen

V G Nielsen1

  • 1Department of Anesthesiology, The University of Alabama at Birmingham, Birmingham, AL 35249-6810, USA. vnielsen@uab.edu

Acta Anaesthesiologica Scandinavica
|August 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of heme modulation in inhibition of Atheris, Atractaspis, Causus, Cerastes, Echis, and Macrovipera hemotoxic venom activity.

Human & experimental toxicology·2018
Same author

Effects of iron and carbon monoxide on Lachesis muta muta venom-mediated degradation of plasmatic coagulation.

Human & experimental toxicology·2016
Same author

Iron and carbon monoxide prevent degradation of plasmatic coagulation by thrombin-like activity in rattlesnake venom.

Human & experimental toxicology·2015
Same author

Old mineshaft, new canary: can circulating osteopontin concentrations predict septic shock?

Minerva anestesiologica·2014
Same author

Hydroxyethyl starch does not decrease prothrombin to thrombin conversion.

Acta anaesthesiologica Scandinavica·2008
Same author

A ROTEM-based method of drug assessment developed with human experimentation without consent.

Acta anaesthesiologica Scandinavica·2007

Colloids impair blood clotting by affecting fibrinogen and Factor XIII interactions. Restoring these factors partially improves coagulation, suggesting targets for clinical intervention to mitigate colloid-induced bleeding risks.

Area of Science:

  • Biochemistry
  • Hematology
  • Physiology

Background:

  • Colloid administration is common in clinical settings.
  • Colloid-mediated hypocoagulability (reduced blood clotting) is a known complication.
  • The precise mechanisms behind this coagulopathy are not fully understood.

Purpose of the Study:

  • To investigate how different colloids, including hydroxyethyl starches (HES) and albumin, affect plasma coagulation.
  • To elucidate the specific molecular mechanisms responsible for colloid-induced impairment of blood clot formation.
  • To identify potential therapeutic targets for counteracting colloid-related bleeding risks.

Main Methods:

  • Plasma samples were diluted with saline, various HES solutions, or albumin.
  • Diluted samples were supplemented with fibrinogen (FI), thrombin (FIIa), or activated Factor XIII (FXIIIa).

Related Experiment Videos

  • Thrombelastography was used to measure clot propagation and strength, assessing the impact of colloids and supplements.

    • Main Results:

    • Dilution with NaCl, HES, and albumin significantly reduced clot propagation and strength.
    • Fibrinogen supplementation normalized clotting in NaCl-diluted plasma but only partially in colloid-diluted plasma.
    • Thrombin and Factor XIIIa supplementation showed varied, partial improvements in clot parameters depending on the colloid used.

    Conclusions:

    • Colloids compromise plasma coagulation primarily by interfering with Factor IIa-fibrinogen and Factor XIIIa-fibrin polymer interactions.
    • Partial restoration of coagulation was observed with fibrinogen and Factor XIIIa supplementation.
    • Further clinical investigation into enhancing Factor XIII activity and fibrinogen levels is warranted to manage colloid-induced hypocoagulability.